CRISPR Therapeutics AG
CRSP
$54.13
-$0.19-0.35%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -53.35% | -264.49% | 56.59% | 32.01% | -8.42% |
| Total Depreciation and Amortization | -1.84% | -2.19% | 2.17% | -2.19% | 0.25% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 374.21% | 230.76% | -53.63% | -5.45% | 40.57% |
| Change in Net Operating Assets | -130.11% | 325.21% | 39.65% | -484.71% | -95.02% |
| Cash from Operations | -111.10% | -7.83% | 53.20% | -11.85% | -187.09% |
| Capital Expenditure | 43.20% | 18.90% | -15.98% | 69.02% | 1.94% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 458.56% | -118.43% | 165.73% | -27.88% | -30.00% |
| Cash from Investing | 454.22% | -118.67% | 165.49% | -27.34% | -29.76% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -78.67% | -37.26% | 75.06% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -78.67% | -37.26% | 75.06% | 2,168.67% | -100.15% |
| Foreign Exchange rate Adjustments | 95.12% | 147.13% | -216.00% | 3,650.00% | 118.18% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 34.10% | -186.89% | 128.05% | -16.08% | -170.14% |